Reviving Value as a Drug Comes Off Patent
5 minutes read · 17th Juni 2025
Pharmaceutical Insights
In pharmaceutical manufacturing, a product’s patent expiry is often viewed as the beginning of the end. Once the exclusivity window closes, generics rush in, margins collapse, and attention swiftly shifts to newer, more profitable products. Once central to the business, these drugs are often kept running just well enough to meet obligations while the company prepares for decline.
But what if manufacturers could produce those drugs in a way that made them competitive even at the end of their patents? That’s exactly what improving efficiency can do in these situations — breathe new life in to pharmaceuticals that are set to come off-patent. This is especially true when expected demand forecasts are disrupted by new indications for alternative conditions or generics are slower than anticipated in coming online resulting in an unexpected surge in demand.
The downward shift: When a drug loses its patent
The moment a product approaches the end of its patent protection, strategic focus begins to fade. Forecasting can become more uncertain. Commercial teams often reallocate attention to upcoming launches. Manufacturing leaders are asked to “just keep it going” — ideally without asking for more resources.
It’s no surprise that operations begin to suffer:
- Investment in new technologies can be de-prioritized.
- CapEx is deemed unjustifiable — with too little time left for a clear return on investment.
- Experienced operators move on to newer lines.
- Efficiency efforts taper off, as it’s assumed there’s little left to gain from a line on its way out.
But operations aren’t the only thing that begins to suffer. Patients depend on these drugs. When production diminishes the cost is great. Manufacturers who take a different approach to drugs coming off patent not only hold a strong competitive advantage, but ensure critical drugs are getting to the patients who need them the most.
With a strategic focus on the areas of operational improvement that will yield the highest returns, pharmaceutical manufacturers can leverage newfound efficiencies to remain competitive and meet prolonged patient demand — without CapEx.
The only question left to ask is: how can manufacturers take advantage of this opportunity?
Turning the tables: Finding hidden capacity without CapEx
Rather than default to costly and slow infrastructure upgrades, Chartwell, with deep experience in late-stage drug manufacturing, recommends increasing capacity and efficiency with what manufacturers already have in place. Through an Opportunity Scan, manufacturers can identify several key areas of improvement across changeovers, labor allocation and cycle time reduction. Working side by side with operators and team leaders, Chartwell runs a rapid series of improvement sprints. The result are real, embedded habits on the shop floor — not theoretical changes, but practical ones, implemented at speed.
Chartwell Partner Jon Willis explains: “Initial skepticism tends to be high when we meet with clients and share that they can make large, rapid capacity increases with the assets that already exist and resources that they have already budgeted for. After 15 to 20 years of manufacture, it is easy to believe that most low-hanging fruit has been picked. But a closer look usually reveals surprising gaps and opportunities; especially when it comes to drugs coming off patent.
“When working with clients, we first conduct an Opportunity Scan. This is a deep dive into a site or multiple sites’ operations. During this phase, we pinpoint very specific, tangible improvement areas that, when implemented effectively, yield strong results. Within weeks clients see significant improvements to their operations. Pharmaceuticals that were thought to be at the end of their life are now not only able to compete with generics, but enable investment in new drugs coming to market.“
Restoring pride: More than just metrics
What changes isn’t just the output. The people who work on the line — some of whom may feel like they are managing a product in decline — begin to rediscover the value of what they are doing.
“It’s so important to get the entire Operations team involved. When people know their ideas are heard and their process knowledge matters, teams deliver real business value, even for those drugs facing patent expiry,” says Jon.
The line, once seen as a burden, now is re-framed as a competitive advantage — one that can still generate margin, protect market share, and support patients.
A new perspective on the patent cliff
This perspective offers a powerful counterpoint to the usual narrative around patent expiry. Instead of treating drugs coming off-patent as operational dead weight, pharma companies can rethink their end-of-lifecycle strategy.
- Old lines can be revitalized with focused operational support.
- Demand surprises don’t have to be crises — if manufacturers know how to respond without relying on CapEx.
- Staff on mature products can be re-energized by being given the tools and support to drive performance.
- ROI can still be achieved — even when time horizons are short and uncertainty is high.
For any manufacturing leader facing the challenge of sustaining drug value, Chartwell shows what’s possible when manufacturers stop seeing a mature product as a liability — and start seeing it as a latent asset.